II. Indications
- Peripheral T Cell Lymphoma (refractory or resistant)
III. Mechanism
- Antimetabolite, Antineoplastic Agent
- Belinostat inhibits tumor cell division, differentiation and Angiogenesis
- Histone Deacetylase Inhibitor (HDAC Inhibitor, hydroxamic acid-type)
- Histones are the spools around which DNA are wrapped, and which play a role in gene expression
- Cancers may be facilitated by abnormally expressed genes in specific histone regions
- HDAC Inhibitors block histone deacetylase
- Histone deacetylase is an enzyme that catalyzes removal of acetyl groups from core histones
- Results in hyperacetylation of histones, suppressing gene expression and cell differentiation
- Belinostat may also down regulate thymidylate synthase
- Sensitizes resistant tumor cells to other antineoplastics
IV. Medications
- Belinostat powder 500 mg for injection
V. Dosing
- Adult: 1000 mg/m2 IV daily on days 1 to 5 of a 21 day Chemotherapy cycle
VI. Adverse Effects
- Thrombocytopenia
- Neutropenia
- Hepatotoxicity
- Tumor Lysis Syndrome
VII. Safety
- Avoid in Pregnancy (any trimester)
- Fetal toxicity
- Use reliable Contraception
- Unknown safety in Lactation
- Monitoring
VIII. Resources
Images: Related links to external sites (from Bing)
Related Studies
Definition (NCI_NCI-GLOSS) | A substance being studied in the treatment of cancer. Belinostat blocks enzymes needed for cell division and may kill cancer cells. It also prevents the growth of blood vessels needed for tumors to grow and may make tumor cells more sensitive to other anticancer drugs. It is a type of histone deacetylase (HDAC) inhibitor, a type of angiogenesis inhibitor, and a type of chemosensitizer. |
Definition (NCI) | A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase. |
Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
MSH | C487081 |
English | Belinostat, belinostat, 2-Propenamide, N-hydroxy-3-(3-((phenylamino)sulfonyl)phenyl)-, BELINOSTAT |